Oficina de Análisis del Plan de Salud, Subgerencia Técnica del Plan de Salud, Gerencia de Administración del Plan de Salud, Banco de México, Mexico City, Mexico.
Facultad de Medicina, Centro de Investigación en Políticas, Población y Salud, Universidad Nacional Autónoma de México, Mexico City, Mexico.
PLoS One. 2021 Jul 21;16(7):e0254946. doi: 10.1371/journal.pone.0254946. eCollection 2021.
Urine self-sampling for human papillomavirus (HPV)-based cervical cancer screening is a non-invasive method that offers several logistical advantages and high acceptability, reducing barriers related to low screening coverage. This study developed and evaluated the performance of a low-cost urine self-sampling method for HPV-testing and explored the acceptability and feasibility of potential implementation of this alternative in routine screening.
A series of sequential laboratory assays examined the impact of several pre-analytical conditions for obtaining DNA from urine and subsequent HPV detection. Initially, we assessed the effect of ethylaminediaminetetraacetic acid (EDTA) as a DNA preservative examining several variables including EDTA concentration, specimen storage temperature, time between urine collection and DNA extraction, and first-morning micturition versus convenience sample collection. We further evaluated the agreement of HPV-testing between urine and clinician-collected cervical samples among 95 women. Finally, we explored the costs of self-sampling supplies as well as the acceptability and feasibility of urine self-sampling among women and healthcare workers.
Our results revealed higher DNA concentrations were obtained when using a 40mM EDTA solution, storing specimens at 25°C and extracting DNA within 72 hrs. of urine collection, regardless of using first-morning micturition or a convenience sampling. We observed good agreement (Kappa = 0.72) between urine and clinician-collected cervical samples for HPV detection. Furthermore, urine self-sampling was an affordable method (USD 1.10), well accepted among cervical cancer screening users, healthcare workers, and decision-makers.
These results suggest urine self-sampling is feasible and appropriate alternative for HPV-testing in HPV-based screening programs in lower-resource contexts.
尿液自我采样进行人乳头瘤病毒(HPV)为基础的宫颈癌筛查是一种非侵入性的方法,具有许多后勤优势和高接受性,降低了与低筛查覆盖率相关的障碍。本研究开发并评估了一种低成本的尿液自我采样方法用于 HPV 检测的性能,并探讨了这种替代方法在常规筛查中潜在实施的可接受性和可行性。
一系列顺序实验室检测研究了从尿液中获得 DNA 以及随后 HPV 检测的几种预分析条件的影响。最初,我们评估了乙二胺四乙酸(EDTA)作为 DNA 防腐剂的效果,考察了 EDTA 浓度、标本储存温度、尿液采集与 DNA 提取之间的时间以及晨尿与方便样本采集等几个变量。我们进一步评估了 95 名女性中尿液和临床医生收集的宫颈样本之间 HPV 检测的一致性。最后,我们探讨了自我采样用品的成本以及女性和医疗保健工作者对尿液自我采样的可接受性和可行性。
我们的结果表明,当使用 40mM EDTA 溶液、在 25°C 下储存标本并在尿液采集后 72 小时内提取 DNA 时,获得的 DNA 浓度更高,无论使用晨尿还是方便采样。我们观察到尿液和临床医生收集的宫颈样本之间 HPV 检测的一致性较好(Kappa = 0.72)。此外,尿液自我采样是一种经济实惠的方法(1.10 美元),得到了宫颈癌筛查使用者、医疗保健工作者和决策者的认可。
这些结果表明,在资源较少的情况下,尿液自我采样对于 HPV 为基础的筛查项目中的 HPV 检测是可行和适当的替代方法。